- Home
- CTKB vs AAMI Comparison
CTKB vs AAMI Comparison
Compare CTKB & AAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTKB
- AAMI
- Stock Information
- Founded
- CTKB 1990
- AAMI 1980
- Country
- CTKB United States
- AAMI United States
- Employees
- CTKB N/A
- AAMI N/A
- Industry
- CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
- AAMI Investment Managers
- Sector
- CTKB Health Care
- AAMI Finance
- Exchange
- CTKB Nasdaq
- AAMI Nasdaq
- Market Cap
- CTKB 879.8M
- AAMI 964.3M
- IPO Year
- CTKB 2021
- AAMI N/A
- Fundamental
- Price
- CTKB $5.88
- AAMI $25.63
- Analyst Decision
- CTKB Strong Buy
- AAMI
- Analyst Count
- CTKB 2
- AAMI 0
- Target Price
- CTKB $9.25
- AAMI N/A
- AVG Volume (30 Days)
- CTKB 758.4K
- AAMI 242.3K
- Earning Date
- CTKB 02-26-2025
- AAMI 02-06-2025
- Dividend Yield
- CTKB N/A
- AAMI 0.16%
- EPS Growth
- CTKB N/A
- AAMI N/A
- EPS
- CTKB N/A
- AAMI 1.65
- Revenue
- CTKB $201,210,000.00
- AAMI $469,000,000.00
- Revenue This Year
- CTKB $8.18
- AAMI $16.77
- Revenue Next Year
- CTKB $11.15
- AAMI $8.38
- P/E Ratio
- CTKB N/A
- AAMI $15.46
- Revenue Growth
- CTKB 9.88
- AAMI 12.17
- 52 Week Low
- CTKB $4.66
- AAMI $20.18
- 52 Week High
- CTKB $9.33
- AAMI $31.52
- Technical
- Relative Strength Index (RSI)
- CTKB 41.85
- AAMI N/A
- Support Level
- CTKB $5.37
- AAMI N/A
- Resistance Level
- CTKB $7.30
- AAMI N/A
- Average True Range (ATR)
- CTKB 0.40
- AAMI 0.00
- MACD
- CTKB -0.14
- AAMI 0.00
- Stochastic Oscillator
- CTKB 26.42
- AAMI 0.00
About CTKB Cytek Biosciences Inc.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.